全 民 健 康 保 險 年 報
National Health Insurance In Taiwan
2013-2014
ANNUAL REPORT
A. New items qualifying forHTA:
1.
New compound drugs or drugs with new active
ingredients or new administration methods that are to be
introduced in the domesticmarket within five years, have
a unit cost of more than NT$10 and have an estimated
market of more thanNT$100million a year
2.
Medical devices with new functions that are to be
introduced in the domestic market within five years with
an estimatedmarket of more thanNT$30million a year
B. For proposals to add to or change the reimbursement
fee schedule:
1.
Drugs: Drugs that could cost the NHI system an
additional NT$50million a year
2.
Medical devices: Devices that could cost the NHI system
an additional NT$30million a year
(
一 ) 新收載案件：
1.
於國內
5
年內上市之新成分、新給
藥途徑、新療效複方藥品，其藥品
單價大於
10
元，且建議者預估每
年費用超過
1
億者。
2.
於國內
5
年內上市之新功能類別特
材，且建議者預估每年費用超過
3
仟萬者。
(
二 ) 藥物給付規定新增或修訂案件：
1.
藥品案件：對健保財務衝擊影響每
年增加超過
5
仟萬者。
2.
特材案件：對健保財務衝擊影響每
年增加超過
3
仟萬者。